| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
40,080,000 |
| Market
Cap: |
16.04(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4002 - $0.4002 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. Co.'s business segments are: Specialized BioTherapeutics, which is developing and moving toward potential commercialization of HyBryte™, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma; and Public Health Solutions, which includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and other infectious disease and its vaccine programs targeting filoviruses and CiVax™, its vaccine candidate for the prevention of COVID-19.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Buhrman Cyrille F |
Director |
– • – |
2007-06-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,900,020 |
|
- |
|
| Myrianthopoulos Evan |
Chief Financial Officer |
• • – |
2007-02-09 |
4 |
B |
$0.47 |
$25,000 |
D/D |
53,191 |
154,817 |
2.81 |
- |
|
| Schaber Christopher |
Chief Executive Officer |
• • – |
2007-02-09 |
4 |
B |
$0.47 |
$100,000 |
D/D |
212,766 |
292,766 |
2.81 |
- |
|
| Clavijo James |
Controller/Treasurer |
• – – |
2007-02-09 |
4 |
B |
$0.47 |
$25,000 |
D/D |
53,191 |
53,191 |
2.74 |
- |
|
| Kanzer Steve H |
Director |
– • – |
2007-02-09 |
4 |
B |
$0.47 |
$100,000 |
D/D |
212,766 |
1,282,203 |
2.39 |
- |
|
| Schaber Christopher |
President and CEOOfficer |
• • – |
2006-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
80,000 |
|
- |
|
| Myrianthopoulos Evan |
Chief Financial Officer |
• • – |
2006-04-10 |
4 |
A |
$0.28 |
$25,000 |
D/D |
90,220 |
90,220 |
|
- |
|
| Sember Michael T |
Chief Executive Officer |
• • – |
2006-04-10 |
4 |
A |
$0.45 |
$81,198 |
D/D |
180,440 |
180,440 |
|
- |
|
| Kanzer Steve H |
officerTitle |
– • – |
2006-01-20 |
4 |
OE |
$0.20 |
$50,000 |
D/D |
250,000 |
1,069,437 |
|
- |
|
| Elan Pharmaceutical Investments Ltd |
10% Owner |
– – • |
2004-02-13 |
4 |
S |
$1.01 |
$1,328,565 |
I/I |
(1,306,300) |
162,600 |
|
- |
|
| Rosenwald Lindsay A Md |
10% Owner |
– – • |
2004-02-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(886,399) |
3,230,922 |
|
- |
|
| Elan Pharmaceutical Investments Ii Ltd |
10% Owner |
– – • |
2004-02-12 |
4 |
S |
$1.01 |
$272,539 |
I/I |
(266,500) |
1,468,900 |
|
- |
|
| Elan Pharmaceutical Investments Ii Ltd |
10% Owner |
– – • |
2004-02-11 |
4 |
S |
$1.05 |
$342,035 |
I/I |
(317,479) |
1,735,400 |
|
- |
|
| Kanzer Steve H |
Director |
– • – |
2003-11-25 |
4 |
B |
$0.75 |
$3,750 |
D/D |
5,000 |
819,437 |
2.31 |
- |
|
| Kanzer Steve H |
Director |
– • – |
2003-09-15 |
4 |
A |
$0.80 |
$100,000 |
I/I |
125,628 |
125,628 |
|
- |
|
| Elan Pharmaceutical Investments Ltd |
10% Owner |
– – • |
2002-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
500,000 |
2,052,879 |
|
- |
|
| Elan Pharmaceutical Investments Ltd |
10% Owner |
– – • |
2002-10-21 |
4 |
OE |
$8.86 |
$11,032,357 |
I/I |
1,245,187 |
1,552,879 |
|
- |
|
92 Records found
|
|
Page 4 of 4 |
|
|
